Selected research
Industry Research
Vaccine Conjugate Industry Research Report 2026
Market perspective
The global Vaccine Conjugate market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Vaccine Conjugate is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Vaccine Conjugate is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Vaccine Conjugate is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Vaccine Conjugate include Bharat Biotech, Beijing Minhai Biotechnology, Beijing Xiangrui Biological Products, Chengdu Olymvax Biopharmaceuticals, GSK, Pfizer, CanSinoBIO, Royal (Wuxi) Bio-Pharmaceutical and Merck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Vaccine Conjugate market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Vaccine Conjugate Market by Company
Bharat Biotech
Beijing Minhai Biotechnology
Beijing Xiangrui Biological Products
Chengdu Olymvax Biopharmaceuticals
GSK
Pfizer
CanSinoBIO
Royal (Wuxi) Bio-Pharmaceutical
Merck
Sanofi
Walvax Biotechnology
Zhifei Biologic
Vaccine Conjugate Segment by Type
Hib Vaccine
Pneumococcal Vaccine
Meningococcal Vaccine
Others
Vaccine Conjugate Segment by Application
Children
Adult
Vaccine Conjugate Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine Conjugate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vaccine Conjugate and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine Conjugate.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Vaccine Conjugate manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Vaccine Conjugate by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Vaccine Conjugate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Hib Vaccine
- Pneumococcal Vaccine
- Meningococcal Vaccine
- Others
Applications
- Children
- Adult
Companies covered
- Bharat Biotech
- Beijing Minhai Biotechnology
- Beijing Xiangrui Biological Products
- Chengdu Olymvax Biopharmaceuticals
- GSK
- Pfizer
- CanSinoBIO
- Royal (Wuxi) Bio-Pharmaceutical
- Merck
- Sanofi
- Walvax Biotechnology
- Zhifei Biologic
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Vaccine Conjugate Market Size (2021-2032)
- 2.2.2 Global Vaccine Conjugate Sales (2021-2032)
- 2.2.3 Global Vaccine Conjugate Market Average Price (2021-2032)
- 2.3 Vaccine Conjugate by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Hib Vaccine
- 2.3.3 Pneumococcal Vaccine
- 2.3.4 Meningococcal Vaccine
- 2.3.5 Others
- 2.4 Vaccine Conjugate by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Children
- 2.4.3 Adult
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Vaccine Conjugate Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Vaccine Conjugate Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Vaccine Conjugate Revenue of Manufacturers (2021-2026)
- 3.4 Global Vaccine Conjugate Average Price by Manufacturers (2021-2026)
- 3.5 Global Vaccine Conjugate Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Vaccine Conjugate, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Vaccine Conjugate, Product Type & Application
- 3.8 Global Manufacturers of Vaccine Conjugate, Established Date
- 3.9 Global Vaccine Conjugate Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bharat Biotech
- 4.1.1 Bharat Biotech Company Information
- 4.1.2 Bharat Biotech Business Overview
- 4.1.3 Bharat Biotech Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bharat Biotech Vaccine Conjugate Product Portfolio
- 4.1.5 Bharat Biotech Recent Developments
- 4.2 Beijing Minhai Biotechnology
- 4.2.1 Beijing Minhai Biotechnology Company Information
- 4.2.2 Beijing Minhai Biotechnology Business Overview
- 4.2.3 Beijing Minhai Biotechnology Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Beijing Minhai Biotechnology Vaccine Conjugate Product Portfolio
- 4.2.5 Beijing Minhai Biotechnology Recent Developments
- 4.3 Beijing Xiangrui Biological Products
- 4.3.1 Beijing Xiangrui Biological Products Company Information
- 4.3.2 Beijing Xiangrui Biological Products Business Overview
- 4.3.3 Beijing Xiangrui Biological Products Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Beijing Xiangrui Biological Products Vaccine Conjugate Product Portfolio
- 4.3.5 Beijing Xiangrui Biological Products Recent Developments
- 4.4 Chengdu Olymvax Biopharmaceuticals
- 4.4.1 Chengdu Olymvax Biopharmaceuticals Company Information
- 4.4.2 Chengdu Olymvax Biopharmaceuticals Business Overview
- 4.4.3 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Product Portfolio
- 4.4.5 Chengdu Olymvax Biopharmaceuticals Recent Developments
- 4.5 GSK
- 4.5.1 GSK Company Information
- 4.5.2 GSK Business Overview
- 4.5.3 GSK Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GSK Vaccine Conjugate Product Portfolio
- 4.5.5 GSK Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Vaccine Conjugate Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 CanSinoBIO
- 4.7.1 CanSinoBIO Company Information
- 4.7.2 CanSinoBIO Business Overview
- 4.7.3 CanSinoBIO Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 CanSinoBIO Vaccine Conjugate Product Portfolio
- 4.7.5 CanSinoBIO Recent Developments
- 4.8 Royal (Wuxi) Bio-Pharmaceutical
- 4.8.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
- 4.8.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
- 4.8.3 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Product Portfolio
- 4.8.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
- 4.9 Merck
- 4.9.1 Merck Company Information
- 4.9.2 Merck Business Overview
- 4.9.3 Merck Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Merck Vaccine Conjugate Product Portfolio
- 4.9.5 Merck Recent Developments
- 4.10 Sanofi
- 4.10.1 Sanofi Company Information
- 4.10.2 Sanofi Business Overview
- 4.10.3 Sanofi Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Sanofi Vaccine Conjugate Product Portfolio
- 4.10.5 Sanofi Recent Developments
- 4.11 Walvax Biotechnology
- 4.11.1 Walvax Biotechnology Company Information
- 4.11.2 Walvax Biotechnology Business Overview
- 4.11.3 Walvax Biotechnology Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Walvax Biotechnology Vaccine Conjugate Product Portfolio
- 4.11.5 Walvax Biotechnology Recent Developments
- 4.12 Zhifei Biologic
- 4.12.1 Zhifei Biologic Company Information
- 4.12.2 Zhifei Biologic Business Overview
- 4.12.3 Zhifei Biologic Vaccine Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Zhifei Biologic Vaccine Conjugate Product Portfolio
- 4.12.5 Zhifei Biologic Recent Developments
5 Global Vaccine Conjugate Market Scenario by Region
- 5.1 Global Vaccine Conjugate Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Vaccine Conjugate Sales by Region: 2021-2032
- 5.2.1 Global Vaccine Conjugate Sales by Region: 2021-2026
- 5.2.2 Global Vaccine Conjugate Sales by Region: 2027-2032
- 5.3 Global Vaccine Conjugate Revenue by Region: 2021-2032
- 5.3.1 Global Vaccine Conjugate Revenue by Region: 2021-2026
- 5.3.2 Global Vaccine Conjugate Revenue by Region: 2027-2032
- 5.4 North America Vaccine Conjugate Market Facts & Figures by Country
- 5.4.1 North America Vaccine Conjugate Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Vaccine Conjugate Sales by Country (2021-2032)
- 5.4.3 North America Vaccine Conjugate Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Vaccine Conjugate Market Facts & Figures by Country
- 5.5.1 Europe Vaccine Conjugate Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Vaccine Conjugate Sales by Country (2021-2032)
- 5.5.3 Europe Vaccine Conjugate Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Vaccine Conjugate Market Facts & Figures by Country
- 5.6.1 Asia Pacific Vaccine Conjugate Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Vaccine Conjugate Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Vaccine Conjugate Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Vaccine Conjugate Market Facts & Figures by Country
- 5.7.1 South America Vaccine Conjugate Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Vaccine Conjugate Sales by Country (2021-2032)
- 5.7.3 South America Vaccine Conjugate Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Vaccine Conjugate Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Vaccine Conjugate Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Vaccine Conjugate Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Vaccine Conjugate Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Vaccine Conjugate Sales by Type (2021-2032)
- 6.1.1 Global Vaccine Conjugate Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Vaccine Conjugate Sales Market Share by Type (2021-2032)
- 6.2 Global Vaccine Conjugate Revenue by Type (2021-2032)
- 6.2.1 Global Vaccine Conjugate Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Vaccine Conjugate Revenue Market Share by Type (2021-2032)
- 6.3 Global Vaccine Conjugate Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Vaccine Conjugate Sales by Application (2021-2032)
- 7.1.1 Global Vaccine Conjugate Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Vaccine Conjugate Sales Market Share by Application (2021-2032)
- 7.2 Global Vaccine Conjugate Revenue by Application (2021-2032)
- 7.2.1 Global Vaccine Conjugate Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Vaccine Conjugate Revenue Market Share by Application (2021-2032)
- 7.3 Global Vaccine Conjugate Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Vaccine Conjugate Value Chain Analysis
- 8.1.1 Vaccine Conjugate Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Vaccine Conjugate Production Mode & Process
- 8.2 Vaccine Conjugate Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Vaccine Conjugate Distributors
- 8.2.3 Vaccine Conjugate Customers
9 Global Vaccine Conjugate Analyzing Market Dynamics
- 9.1 Vaccine Conjugate Industry Trends
- 9.2 Vaccine Conjugate Industry Drivers
- 9.3 Vaccine Conjugate Industry Opportunities and Challenges
- 9.4 Vaccine Conjugate Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst